Hosted on MSN6mon
Trial shows timing matters when adding immunotherapy to chemoradiation for limited-stage small cell lung cancer
Earlier this year, the landmark phase III ADRIATIC trial found adding a similar immunotherapy agent (durvalumab ... chemoradiation with or without atezolizumab immunotherapy.
ascopubs.org4d
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non–Small Cell Lung Cancer
AFT-16 also explored neoadjuvant atezolizumab before concurrent chemoradiotherapy to a standard 60 Gy in 30 fractions, followed by adjuvant atezolizumab, and showed an 18-month OS of 84%. 32 While ...
Cancer Therapy Advisor4d
ICIs Outperform Chemo for MSI-H mCRC in First Line but Not in Later Lines
Patients with MSI-H mCRC had a higher probability of survival with first-line ICI therapy than with chemotherapy, but second-line or later ICIs did not confer the same benefit.
The American Journal of Managed Care9d
Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC
Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...
Monthly Prescribing Reference24d
Durvalumab Plus FLOT Improves Event Free Survival in Gastric/GEJ Cancer
The study met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement in EFS with the durvalumab regimen vs the placebo regimen. Topline results were ...